ClinicalTrials.gg
Status unknownNCT03864978Updated Mar 11, 2019

Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test

A Phase 2 interventional study of Rifaximin delayed release 400 mg tablet and Placebo in Papulopustular Rosacea, sponsored by Alfasigma S.p.A.. Status unknown at 12 sites in Italy. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-03-11.

Sponsored by Alfasigma S.p.A. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2019), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jun 2018, registered Mar 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Preliminary evidence suggests that treatment with rifaximin may be beneficial in patients with papulopustular rosacea.

The present clinical trial is aimed to investigate the safety and efficacy of oral rifaximin delayed release versus placebo in adults with moderate-to-severe papulopustular rosacea (a.k.a. subtype II) and positive lactulose H2/CH4 breath test.

02

Conditions studied

  • Papulopustular Rosacea

Browse trials for

03

In context

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

This study's planned enrollment of 236 is above the median of 61 across 200 interventional studies indexed under Rosacea.

Browse Rosacea studies →

Lead sponsor

Alfasigma S.p.A. is the lead sponsor of 24 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion Criteria:

  1. Men and women aged 18 to 70 years at screening.
  2. Female participants are eligible if they are either of non- or of childbearing potential with a negative pregnancy test result at screening and randomization and agreeing to use a highly effective method of until 72 hours after taking the last study treatment dose.
  3. Moderate-to-severe papulopustular rosacea (a.k.a. subtype II, RII) at screening and confirmed at randomization. Moderate-to-severe rosacea is defined as the presence of 11 or more facial papules or pustules with or without plaques.
  4. Positivity of lactulose H2/CH4 breath test (L-BT) within the last 2-weeks before randomization.
  5. Patients accepting to provide and legally capable of providing free and to all procedures included in the protocol (including facial skin photography).

Key exclusion Criteria:

  1. Granulomatous rosacea or rosacea fulminans.
  2. Erythematoteleangectatic, phymatous or ocular rosacea only. Patients with these subtypes associated with papulopustular rosacea can be enrolled.
  3. Circulating anti-helicobacter pylori IgM and/or IgG at screening (V1).
  4. Positivity at the faecal Clostridium Difficile toxin assay at screening (V1).
  5. History or family history of inflammatory bowel disease (Crohn's disease or ulcerative colitis) or other conditions characterized by severe intestinal ulcers.
  6. History or family history of coeliac disease.
  7. Patients with intestinal obstruction or partial intestinal obstruction.
  8. Presence of diarrhoea associated with fever and/or blood in the stool.
  9. Health conditions requiring continuous or intermittent treatment with facial topical, inhaled or systemic and/or biologic or non-biologic or immunomodulatory agents (e.g. diseases, etc.).
  10. Severe kidney impairment (i.e. estimated \<30 ml/min).
  11. Severe hepatic impairment (i.e. B or C).
  12. Cancer or any cancer-related treatment within 5 years prior to screening (excluding non-melanoma skin-cancer).
  13. History of alcohol or drug abuse within a year prior to screening.
  14. Facial skin conditions that can interfere with reliable assessment of rosacea throughout the study (e.g. keloids, hypertrophic scarring, recent facial surgery etc.)
  15. Any other significant health condition (e.g. cardiovascular, respiratory, renal, hepatic, neurologic, psychiatric, hematologic, oncologic, immune etc.) that in the investigator's judgement may: i) jeopardize the patient's safe participation in the trial or ii) make unlikely the patient's completion of the study or iii) make unlikely the patient's compliance with the study procedures (e.g. highly anticipated need of non-permitted treatments, terminal illness, etc.).
  16. History of to rifaximin, rifamycin-derivatives, any of the rifaximin-EIR , or any UV protection cream component.
  17. Treatment with biologic immunomodulatory and/or immunosuppressive drugs (e.g. anti-TNF drugs) within 6 months prior to randomization.
  18. Treatment with non-biologic immunomodulatory and/or immunosuppressive drugs (e.g. cyclosporine, methotrexate etc.) within 30 days prior to randomization.
  19. Treatment with warfarin within 14 days prior to randomization.
  20. Treatment with niacin within 30 days prior to randomization.
  21. Topical facial or systemic antibiotics within 30 days before randomization;
  22. Treatment with neomycin or other low-absorbable oral antibiotics (such as marketed rifaximin) within 90 days before randomization.
  23. Topical facial, inhaled or systemic corticosteroids within 30 days prior to randomization.
  24. Topical facial retinoids within 30 days before randomization.
  25. Systemic retinoids within 6 months before randomization.
  26. Any other topical or systemic treatment for rosacea within 30 days before randomization (including also laser and pulsed light, etc.).
  27. Pharmaceutical prebiotics and probiotics (functional food is allowed), within 30 days before randomization.
  28. Any experimental treatment within 6 months prior to randomization.
  29. Women who are pregnant, breast-feeding or planning a pregnancy during the trial period.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
236 participants (estimated)

Study arms

  • Experimental
    Rifaximin-EIR 800 mg BID for 10 days

    2 x rifaximin delayed release 400 mg tablet twice a day (total daily dose of rifaximin: 1600 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days

    Drug: Rifaximin delayed release 400 mg tablet · Drug: Placebo

  • Experimental
    Rifaximin-EIR 400 mg BID for 30 days

    1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 30 days

    Drug: Rifaximin delayed release 400 mg tablet · Drug: Placebo

  • Experimental
    Rifaximin-EIR 400 mg BID for 10 days

    1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days

    Drug: Rifaximin delayed release 400 mg tablet · Drug: Placebo

  • Placebo comparator
    Two placebo tablets BID for 30 days

    2 x placebo tablets twice a day for 30 days

    Drug: Placebo

Interventions

  • DrugRifaximin delayed release 400 mg tablet

    Rifaximin delayed release

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Mean change from baseline (day 1) in number of rosacea inflammatory lesions (papules, pustules or plaques) at the end of treatment visit (day 30 ± 1)

    changes in number of lesions

    Time frame: 30 days

  2. Percent of participants showing treatment success (IGA score of 0 [clear] or 1 [almost clear]) at the end of treatment visit (day 30 ± 1)

    per cent changes in IGA score 0 and 1 patients

    Time frame: 30 days

Secondary outcomes

  1. Mean change from Baseline (day 1) in number of rosacea inflammatory lesions at the end of treatment visit (day 30 ± 1) as provided by Canfield Image Analysis

    changes respect to baseline

    Time frame: 30 days

  2. Mean change from Baseline (day 1) in number of inflammatory lesions (papules, pustules or plaques) at day 10 ± 1 and day 60 ± 3

    change respect to baseline

    Time frame: 10 and 60 days

  3. Percent of participants showing treatment success (i.e. IGA score of 0 or 1) at day 10 ± 1 and day 60 ± 3

    per cent changes in IGA score 0 and 1 patients

    Time frame: 10 and 60 days

  4. Percent of participants with IGA score of 0 (clear) at day 10 ± 1, day 30 ± 1 and day 60 ± 3

    per cent changes in IGA score 0 patients

    Time frame: 10, 30 and 60 days

  5. Mean change from Baseline (day 1) in the following rosacea additional features at day 10 ± 1, day 30 ± 1 and day 60 ± 3: • burning or stinging • telangiectasia • ocular manifestations • phymatous changes

    change respect to baseline

    Time frame: 10, 30 and 60 days

  6. Mean change from Baseline (day 1) in facial non-transient erythema at day 10 ± 1, day 30 ± 1 and day 60 ± 3 (absent=0, mild=1, moderate=2, severe=3)

    change respect to baseline

    Time frame: 10, 30 and 60 days

  7. Mean change from Baseline (day 1) in number of inflammatory lesions at day 10 ± 1 and day 60 ± 3 as provided by Canfield Image Analysis

    change respect to baseline

    Time frame: 10 and 60 days

  8. Mean change from Baseline (day 1) in facial non-transient erythema score at day 10 ± 1, day 30 ± 1 and day 60 ± 3, based on global fractional area redness as provided by Canfield Image Analysis

    change respect to baseline

    Time frame: 10, 30 and 60 days

  9. Mean change from Baseline in Basic Self-Esteem Scale at day 30 ± 1 and day 60 ± 3

    change respect to previous evaluation

    Time frame: 30 and 60 days

  10. Mean change from Baseline (day 1) in Dermatology Life Quality Index (10-item DLQI) at day 30 ± 1 and day 60 ± 3

    change respect to baseline

    Time frame: 30 and 60 days

  11. Mean difference in Treatment Satisfaction Questionnaire between study groups at day 30 ± 1

    differences between treatment arms

    Time frame: 30 days

Other outcomes

  1. Mean change from Baseline (day 1) in circulating inflammatory marker levels at 10 ± 1, day 30 ± 1 and day 60 ± 3

    change respect to baseline

    Time frame: 10, 30 and 60 days

  2. Mean change from baseline (day 1) skin texture index at 10 ± 1, day 30 ± 1 and day 60 ± 3 as provided by Canfield Image Analysis

    change respect to baseline

    Time frame: 10, 30 and 60 days

07

Study locations

12 of 12 sites recruiting
  • Ospedali Riuniti di Ancona
    Ancona, Italy
    Recruiting
  • Policlinico di Bari
    Bari, Italy
    Recruiting
  • Policlinico Sant'Orsola Malpighi
    Bologna, Italy
    Recruiting
  • Spedali Civili
    Brescia, Italy
    Recruiting
  • Policlinico Vittorio Emanuele
    Catania, Italy
    Recruiting
  • Ospedale Policlinico San Martino
    Genova, Italy
    Recruiting
  • Ospedale della Misericordia
    Grosseto, Italy
    Recruiting
  • Policlinico di Modena
    Modena, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Federico II
    Napoli, Italy
    Recruiting
  • Policlinico Universitario A. Gemelli
    Roma, Italy
    Recruiting
  • Azienda Ospedaliera Santa Maria
    Terni, Italy
    Recruiting
  • A.O.U. Città della Salute e della Scienza
    Torino, Italy
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2018 (actual). Primary completion is estimated for Apr 2020, 22 months after the start.

Of 20 phase 2 interventional studies under Rosacea, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's planned 22 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2019
First posted
Mar 6, 2019
StartActual
Jun 22, 2018
Primary completionEst.
Apr 2020
CompletionEst.
Oct 2020
Last update
Mar 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03864978
Lead sponsor
Alfasigma S.p.A.
Responsible party
Sponsor
First posted
Mar 6, 2019
Start date
Jun 22, 2018
Primary completion
Apr 2020 (estimated)
Completion
Oct 2020 (estimated)
Last update
Mar 11, 2019

Study contacts

Alessandro Blè, MD
Contact
alessandro.ble@alfasigma.com
+39-051-6489619

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion